Archive for category: Healthcare

ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting

ARCA Biopharma Announces Issuance of European Patent for Treating Cardiovascular Diseases and Conditions With a New Chemical Entity Utilizing Genetic Targeting

/ November 27, 2017 9:51 am

ARCA Plans Genetically-Targeted Development of a New Chemical Entity (AB171) for Peripheral Arterial Disease and Heart Failure RCA biopharma, Inc. (Nasdaq:ABIO), a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced the European […]

Aequus Granted European Patent for Once-Weekly Transdermal Aripiprazole

Aequus Granted European Patent for Once-Weekly Transdermal Aripiprazole

/ November 27, 2017 9:41 am

Aequus Pharmaceuticals Inc. (TSX-V: AQS, OTCQB: AQSZF) (“ Aequus ” or the “Company”), a specialty pharmaceutical company with a focus on developing, advancing and promoting differentiated products, announced today that the European Patent Office has issued an intention to grant a European […]

OxThera Strengthens Patent Portfolio for treatment of Hyperoxaluria

OxThera Strengthens Patent Portfolio for treatment of Hyperoxaluria

/ November 13, 2017 8:56 am

OxThera AB announced today that it has recently been granted two new US patents, three new European patents and patents in Canada, China, Hong-Kong, India and Japan. OxThera now holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in nine patent families. The newly granted US patents have numbers US8900575 and US8940295 covering pharmaceutical compositions of oxalate decarboxylase. The new European […]

Oramed Granted Broad Composition of Matter Patent in Europe for Oral Proteins

Oramed Granted Broad Composition of Matter Patent in Europe for Oral Proteins

/ November 2, 2017 1:30 pm

Oramed Pharmaceuticals Inc. (NASDAQ/TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today the European Patent Office has issued to Oramed a notice of intent to grant a patent for broader claims […]

Pluristem Expands its Reach in the Treatment of Impaired Hematopoietic Systems with a European Patent Covering PLX-R18 in Chemotherapy, ARS, Genetic Disorders and Autoimmune Diseases

Pluristem Expands its Reach in the Treatment of Impaired Hematopoietic Systems with a European Patent Covering PLX-R18 in Chemotherapy, ARS, Genetic Disorders and Autoimmune Diseases

/ October 27, 2017 8:08 am

Pluristem Therapeutics Inc. (NASDAQ: PSTI, TASE: PSTI), a leading developer of placenta-based cell therapy products, announced today that the European Patent Office has issued the company a patent titled, “Methods for Treating Radiation or Chemical Injury” for its PLX-R18 cell […]

ASIT biotech announces the grant of a European patent on the active ingredients used in the ASIT+™ allergy immunotherapy product candidates

ASIT biotech announces the grant of a European patent on the active ingredients used in the ASIT+™ allergy immunotherapy product candidates

/ October 19, 2017 9:00 am

Brussels, Belgium, October 17, 2017, 6:30 pm (CEST) – ASIT biotech (Euronext: ASIT – BE0974289218), a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, announces the positive […]

BioArctic’s Patent for its Product Candidate Antibody BAN0805, for Parkinson’s Disease, is Now Granted in Europe

BioArctic’s Patent for its Product Candidate Antibody BAN0805, for Parkinson’s Disease, is Now Granted in Europe

/ October 13, 2017 8:53 am

Stockholm, Sweden, October 13, 2017 – BioArctic AB (publ) (Nasdaq Stockholm:BIOA B) today announced that the European Patent Office (EPO) has decided to grant a European patent (EP2539366) to BioArctic AB and the patent will be published on November 08, 2017. […]

CEL-SCI GRANTED EUROPEAN PATENT FOR MULTIKINE’S MECHANISM OF ACTION IN MAKING TUMORS ‘VISIBLE’ TO THE IMMUNE SYSTEM

CEL-SCI GRANTED EUROPEAN PATENT FOR MULTIKINE’S MECHANISM OF ACTION IN MAKING TUMORS ‘VISIBLE’ TO THE IMMUNE SYSTEM

/ October 13, 2017 8:45 am

CEL-SCI Corporation (NYSE American: CVM) announced today that the European Patent Office has issued a new patent to CEL-SCI for its lead investigational immunotherapy, Multikine* (Leukocyte Interleukin, Injection), which is currently in a pivotal Phase 3 trial for head and neck cancer. […]

New Patents Granted to Sabinsa’s Cosmetics Division in US And EU

New Patents Granted to Sabinsa’s Cosmetics Division in US And EU

/ September 26, 2017 12:49 pm

Sabinsa Cosmetics, a division of the Sami Labs – Sabinsa Group, has been granted two new patents on novel cosmetic compositions, both developed from extensive research on combinations of the companies branded ingredients. These most recent patents are likely to […]

Cantargia obtains patent approval in Europe for the antibody CAN04 in development for treatment of cancer

Cantargia obtains patent approval in Europe for the antibody CAN04 in development for treatment of cancer

/ September 14, 2017 10:00 am

Cantargia AB (”Cantargia”) today announced that the European Patent Office (“EPO”) has granted the company’s patent application on the product candidate CAN04. CAN04 is targeted against the molecule IL1RAP expressed in a large number of cancer diseases. The formal approval […]